Loading news...
Cytek Biosciences, Inc. (CTKB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Company to present at the 44th Annual JP Morgan Healthcare Conference Company to present at the 44th Annual JP Morgan Healthcare Conference
Cytek Biosciences, Inc. (NASDAQ: CTKB - Get Free Report) has received a consensus recommendation of "Hold" from the eight research firms that are currently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and four have assigned a buy recommendation to the
Bank of Montreal Can raised its holdings in Cytek Biosciences, Inc. (NASDAQ: CTKB) by 110.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,072 shares of the company's stock after buying an additional 17,379 shares
Cytek Biosciences offers a full-spectrum cytometry platform. This means they provide instruments, reagents, services, and cloud software. Their main value proposition is to allow clients to achieve higher-parameter cell analysis than conventional flow systems. Its core product portfolio centers around Aurora, Northern Lights, Aurora CS, and Aurora Evo. Each targets a different price-performance tier.
FREMONT, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced its inclusion on TIME's 2026 list of America's Growth Leaders.
FREMONT, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) announced today that its Cytek ® Muse ® Micro cell analyzer has been named Drug Discovery Solution of the Year in the 2025 BioTech Breakthrough Awards.
FREMONT, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences.
Cytek Biosciences, Inc. ( CTKB ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Paul Goodson Wenbin Jiang - President, CEO & Chairman of the Board William McCombe - Chief Financial Officer Conference Call Participants David Westenberg - Piper Sandler & Co., Research Division Brendan Smith - TD Cowen, Research Division Harrison Parsons - Stephens Inc., Research Division Noah Lewis - Raymond James & Associates, Inc., Research Division Presentation Operator Good day, everyone, and thank you for standing by. My name is Arjarie, and I will be your conference operator today.
Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of $0.01. This compares to earnings of $0.01 per share a year ago.
FREMONT, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2025.
FREMONT, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amid the reduction of various government grant programs and global economic challenges that have tightened research funding, Cytek Biosciences, Inc. (Nasdaq: CTKB) is taking steps to ensure critical scientific research can continue.
FREMONT, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the third quarter 2025 after market close on Wednesday, November 5, 2025. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.
FREMONT, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- In a move that strengthens its European operations and enhances service for its customers, spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced the relocation of its European headquarters to a new facility in Amsterdam's Life Sciences District.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), announces multiple strategic technology partnerships to advance the Cell Q™, the first fully automated quality control testing platform purpose-built to match the commercial-scale throughput for cell therapy manufacturing. Cellares is unveiling these partnerships ahead of the 10th Annual CAR-TCR Summit, where it will, for the first time, present drug product release da.
FREMONT, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- With cancer research and diagnostics driving the need for deeper, faster cellular insights, spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) will showcase its advanced, high-parameter solutions at two notable industry events later this month: the European Society for Clinical Cell Analysis (ESCCA) 2025 Conference and ICCS 2025, the 40th Annual International Clinical Cytometry Meeting & Course.
Cytek Biosciences, Inc. (NASDAQ:CTKB ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 10:00 AM EDT Company Participants Wenbin Jiang - President, CEO & Chairman of the Board William McCombe - Chief Financial Officer Conference Call Participants Yih-Ming Tu - Morgan Stanley, Research Division Presentation Yih-Ming Tu Research Associate Good morning, everyone. Thank you for joining us on Day 3 of our Global Healthcare Conference.
FREMONT, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences.
Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Paul Goodson - Head of Investor Relations Wenbin Jiang - President, CEO & Chairman of the Board William D. McCombe - Chief Financial Officer Conference Call Participants Chad Wiatrowski - Unidentified Company David Michael Westenberg - Piper Sandler & Co., Research Division Operator Ladies and gentlemen, thank you for standing by.
Cytek Biosciences, Inc. (CTKB) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.08 per share a year ago.